川芎嗪联合非洛地平可增强维持性血液透析患者抗氧化应激能力

张波.川芎嗪联合非洛地平可增强维持性血液透析患者抗氧化应激能力[J].内科急危重症杂志,2022,28(2):125-128

扫码阅读全文

DOI：10.11768/nkjwzzzz20220209

英文关键词:

基金项目:

作者	单位	E-mail
张波	淮南新华医疗集团新华医院	zhangbo4076@163.com

摘要点击次数: 1207

全文下载次数: 1677

中文摘要:

目的：探讨川芎嗪联合非洛地平对维持性血液透析（MHD）患者抗氧化应激能力及残余肾功能（RRF）的影响。方法：选取2018年4月至2020年6月淮南新华医疗集团新华医院血液透析中心采取相同透析方案的70例MHD患者，随机分为对照组和观察组，每组35例。2组患者均给予常规血液透析、非洛地平降压等基础治疗，观察组在基础治疗上加用川芎嗪注射液治疗，40mg/次，3次/周，于透析治疗结束后静脉滴注。比较2组患者治疗前及治疗6个月后尿量、RRF、血液透析充分性 [尿素下降率（URR）、尿素清除指数（KT/V）]、外周血超氧化物歧化酶（SOD）、丙二醛（MDA）及生活质量 [生理健康总测量（PCS）、心理健康总测量（MCS）]评分变化及不良反应发生情况。结果：治疗后，2组患者尿量、RRF均较治疗前下降，且观察组高于对照组（P均<0.05）。观察组URR、KT/V较治疗前显著提高，且治疗后明显高于对照组（P均<0.05）。2组患者SOD水平较治疗前升高，且观察组高于对照组（P均<0.05）；MDA水平较治疗前降低，且观察组低于对照组（P均<0.05）。治疗后，2组患者PCS、MCS评分较干预前降低，且观察组PCS、MCS评分高于对照组（P均<0.05）；2组治疗期间均未见明显的药物不良反应。结论：川芎嗪联合非洛地平可增强MHD患者的抗氧化应激能力，延缓其RRF的下降，提高血液透析充分性及生存质量，且安全性较好。

英文摘要:

Objective: To explore the effects of ligustrazine combined with felodipine on anti oxidative stress ability and residual renal function (RRF) in patients undergoing maintenance hemodialysis (MHD). Methods: A total of 70 patients undergoing MHD in Hemodialysis Center of Xinhua Hospital, Huainan Xinhua Medical Group from April 2018 to June 2020 were enrolled and randomly divided into control group (n=35) and observation group (n=35). Both groups were given basic treatment such as routine hemodialysis and felodipine depressurization. On this basis, observation group was given intravenous drip of ligustrazine injection (40mg/once, 3times/week) after dialysis. The changes in urine output, RRF, hemodialysis adequacy [urea reduction rate (URR), urea clearance index (KT/V)], peripheral blood superoxide dismutase (SOD), malondialdehyde (MDA) and scores of quality of life \[Physical Component Summary (PCS), Mental Component Summary (MCS)\] before treatment and after 6 months of treatment, as well as the occurrence of adverse reactions were compared between the two groups. Results: After treatment, urine output and RRF were decreased in both groups, which were significantly higher in observation group than in control group (P<0.05). After treatment, URR and KT/V in observation group were significantly increased as compared with those in control group (P<0.05). After treatment, SOD level was increased in both groups, which was higher in observation group than in control group (P<0.05), while MDA level was decreased in both groups, which was lower in observation group than in control group (P<0.05). After treatment, scores of PCS and MCS were decreased in both groups, which were higher in observation group than in control group (P<0.05). No significant adverse drug reactions occurred during treatment in either group. Conclusion: Ligustrazine combined with felodipine can enhance anti oxidative stress ability of MHD patients, delay the decline of RRF, improve hemodialysis adequacy and quality of life, with good safety.